Literature DB >> 897223

Prostaglandin-mediated hypercalcemia in the VX2 carcinoma-bearing rabbit.

H W Seyberth, W C Hubbard, O Oelz, B J Sweetman, J T Watson, J A Oates.   

Abstract

Prostaglandin biosynthesis and metabolism were studied in the VX2 carcinoma-bearing rabbit, an animal model of prostaglandin-mediated hypercalcemia. All the identification and quantification of the prostaglandins were done by gas chromatography-mass spectrometry. The tumor incubated in vitro converted exogeneous arachidonic acid principally to PGE2. Biosynthesis from endogenous precursor lipids yields mainly PGE2 and PGF2alpha. The 100,000 x g supernatant fluid of the tumor did not contain any metabolizing enzymes. Significant hypercalcemia developed between the first and second week after tumor implantation. The levels of the major plasma metabolite of PGE2, 15-keto-13,14-dihydro-PGE2, became elevated at one week, had risen 25-fold by the end of the second week, and at the fourth week were elevated to 256 times the pre-incubation levels. The concentration of 15-keto-13,14-dihydro-PGF2alpha in plasma rose in parallell but to a lesser degree. 7alpha-hydroxy-5,11-diketotetranor-prostane-1,16-dioic acid, the major urinary metabolite of the E prostaglandins, was elevated two weeks after tumor implantation and rose until the fifth week. Indomethacin treatment lowered both serum calcium and the plasma level of 15-keto-13,14-dihydro-PGE2.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 897223     DOI: 10.1016/0090-6980(77)90177-0

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  16 in total

Review 1.  Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome.

Authors:  H W Seyberth
Journal:  Klin Wochenschr       Date:  1978-04-15

2.  Canine lymphosarcoma: a model for study of the hypercalcemia of cancer.

Authors:  H Heath; R E Weller; G R Mundy
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

3.  Differentiation of hypercalcaemia due to malignancy from primary hyperparathyroidism: the value of parathyroid hormone and plasma bicarbonate measurements.

Authors:  R Freaney; E Ryan; F P Muldowney
Journal:  Ir J Med Sci       Date:  1981-01       Impact factor: 1.568

4.  Mass spectrometric determination of urinary prostaglandins in preterm infants. The basis for an effective and safe therapeutic regimen for the pharmacological closure.

Authors:  H W Seyberth; H Müller; T Erlenmaier; R Mrongovius
Journal:  Eur J Clin Pharmacol       Date:  1980-07       Impact factor: 2.953

5.  6-Keto-prostaglandin E1-stimulated bone resorption in organ culture.

Authors:  F E Dewhirst
Journal:  Calcif Tissue Int       Date:  1984-07       Impact factor: 4.333

6.  Fatty acid composition of tissue phospholipids and prostaglandin excretion in hyperlipidemia induced in rats by implantation of the mammotropic pituitary tumor MtT-F4.

Authors:  Y S Huang; A Martineau; P Falardeau; J Davignon
Journal:  Lipids       Date:  1983-06       Impact factor: 1.880

7.  Leydig cell tumor induced hypercalcemia in the Fischer rat: morphometric and histochemical evidence for a humoral factor that activates osteoclasts.

Authors:  H Troyer; J R Sowers; E Babich
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

8.  VX2 carcinoma, pulmonary metastases, and neutrophilic leukocytosis. Possible animal model of tumor-associated granulocytosis.

Authors:  A J Hough; W C Hubbard; J A Oates
Journal:  Am J Pathol       Date:  1983-08       Impact factor: 4.307

Review 9.  Hypercalcemia and cancer: an update.

Authors:  T M Murray; R G Josse; J N Heersche
Journal:  Can Med Assoc J       Date:  1978-10-21       Impact factor: 8.262

10.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.